Biopsies from advanced melanoma before and/or after treatment with nivolumab
收藏官方服务：
资源简介：
Biopsies from advanced melanoma before and/or after treatment with nivolumab
应用场景：
创建时间：
2022-01-01
相关数据集
Differential response to Lenalidomide from WT and RUNX1-KO MDS-L del(5q) cells. Differential response to Lenalidomide from WT and RUNX1-KO MDS-L del(5q) cells
We used CRISPR/Cas9 system to generate WT Control and RUNX1-KO MDS-L cells isolated as single clones from the parental MDS-L cell line. We have observed that RUNX1-KO MDS-L cells are resistant to Lena
NIAID Data Ecosystem100
Circulating SOD2 is a Response Biomarker for Neoadjuvant Therapy in Breast Cancer
There is a great need of non-invasive tools that inform of an early molecular response to cancer therapeutic treatment. Here, we have tested the hypothesis that proteolytically resistant proteins coul
NIAID Data Ecosystem60
Correlation of histopathologic characteristics to protein expression and function in malignant melanoma
Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a ver
NIAID Data Ecosystem40
Multi-Omics Biomarkers of Response to Immunotherapy in Combination with Epigenetic Modulators
Epigenetic immunomodulation by association of guadecitabine with ipilimumab (NIBIT-M4 Phase Ib trial, NCT02608437) has been shown to be safe and tolerable in advanced melanoma and to have significant
NIAID Data Ecosystem80
Correlation between MAGE-C1/CT7, MAGE-C2/CT10 and Ki-67 expression in primary melanoma and risk of lymph node metastases.
The expression of MAGE-C1/CT7, MAGE-C2/CT10 and Ki-67 in primary melanoma was determined retrospectively and associated with the presence of SLN metastases. This analysis was performed either separate
NIAID Data Ecosystem40
